$0.00
(Market cap
$11 Mln
Revenue (TTM)
$20 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-57 Mln
-
ROE
-3.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0.4
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
108,022,000
9 Years Aggregate
CFO
$-429.11 Mln
EBITDA
$-458.82 Mln
Net Profit
$-486.53 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ObsEva SA - ADR
| -42.8 | -30.0 | -57.0 | -93.9 | -65.9 | -63.8 | -- |
|
BSE Sensex*
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|
|
ObsEva SA - ADR
| -92.7 | -4.3 | -45.5 | -69.8 | 29.5 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout ObsEva SA - ADR
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor... antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland. Read more
-
CEO & Director
Mr. Brian O'Callaghan
-
CEO & Director
Mr. Brian O'Callaghan
-
Headquarters
Geneva
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ObsEva SA - ADR
What is the current share price of ObsEva SA - ADR Today?
The share price of ObsEva SA - ADR is $0.08 (NASDAQ) as of 21-Apr-2023 09:30 EDT. ObsEva SA - ADR has given a return of -65.94% in the last 3 years.
What is the current PB & PE ratio of ObsEva SA - ADR?
Since, TTM earnings of ObsEva SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of ObsEva SA - ADR?
The 52-week high and low of ObsEva SA - ADR are Rs -- and Rs -- as of 28-Aug-2026.
What is the market cap of ObsEva SA - ADR?
ObsEva SA - ADR has a market capitalisation of $ 11 Mln as on 24-Apr-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in ObsEva SA - ADR?
Before investing in ObsEva SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.